Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies

Isocitrate dehydrogenases 1 and 2 (IDH1,2), the key Krebs cycle enzymes that generate NADPH reducing equivalents, undergo heterozygous mutations in >70% of low- to mid-grade gliomas and ~20% of acute myeloid leukemias (AMLs) and gain an unusual new activity of reducing the α-ketoglutarate (α-KG)...

Descripción completa

Detalles Bibliográficos
Autores principales: Madala, Hanumantha Rao, Punganuru, Surendra R., Arutla, Viswanath, Misra, Subhasis, Thomas, T. J., Srivenugopal, Kalkunte S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836081/
https://www.ncbi.nlm.nih.gov/pubmed/29439493
http://dx.doi.org/10.3390/cancers10020049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836081/
https://www.ncbi.nlm.nih.gov/pubmed/29439493
http://dx.doi.org/10.3390/cancers10020049

Ejemplares similares